A New Wave of Hope
The DEEp OCEAN study is evaluating the investigational medicine bexicaserin for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs). The study has now completed enrollment, marking an important milestone toward understanding the potential of this investigational treatment.
Enrollment Complete for the DEEp OCEAN Study
Lundbeck has completed enrollment for the DEEp OCEAN study, which is evaluating the investigational molecule bexicaserin for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs).
DEEs are a diverse group of rare epilepsies often associated with frequent, treatment-resistant seizures, developmental challenges, and substantial unmet medical needs.
Study results are expected in late 2026 or early 2027.
Learn More
Download the July 2026 DEEp Studies Update below for additional information about the study and what comes next.
Download the DEEp Studies Update – July 2026
Visit the DEEp OCEAN Study Website
The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.
Updated 07/27/26 (KK)